Trifecta Clinical®, a leading global clinical technology solutions provider, announces a strategic partnership with SAFE-BioPharma® to implement the SAFE-BioPharma digital identity and signature standard across its application platforms. The SAFE-BioPharma digital identity and signature standard provides standardized, high-assurance identity trust for cyber-transactions across the biopharmaceutical and healthcare sectors. This will accelerate the adoption of standards-based identity management, enhancing security, quality and compliance. The company also joined SAFE-BioPharma Association’s Vendor Partner Program.
“SAFE-BioPharma digital identity credentials will enhance Trifecta’s ability to quickly and securely exchange data with sponsors, clinical research organization and consortiums, saving money and time. It will simplify complicated processes for our clients as well as investigators,” said Alden Meier, president of Trifecta Clinical.
The SAFE-BioPharma standard was established by the pharmaceutical industry with the participation of the European Medicines Association and the U.S. Food and Drug Administration to create and maintain an interoperable digital identity and signature standard that allows secure, trusted exchanges and legally-binding digital signatures. A distinguishing characteristic of the standard requires each digital identity to be closely bound to its user’s proven identity. This provides a high level of trust in the identity of its user and is the basis of its interoperability. SAFE-BioPharma identity credentials will be trusted by US government agencies such as the National Institutes of Health, Food and Drug Administration and other systems that are directly or indirectly cross-certified with SAFE-BioPharma. SAFE-BioPharma member companies, which include most of the world’s leading biopharmaceutical companies, parallel Trifecta’s client roster.
“We are delighted to welcome Trifecta to the growing SAFE-BioPharma community. Their global reach will accelerate distribution of SAFE-BioPharma digital identity credentials and help us achieve our goal of replacing difficult to manage multiple electronic identities with one, secure and interoperable cyber-identity per medical professional,” said Mollie Shields Uehling, president and CEO, SAFE-BioPharma Association.
Trifecta produces more than 350 live, on-demand, and web-based investigator meetings each year in over 85 countries. Trifecta´s innovative training and portal solutions improve trial quality, speed study start-up and site readiness. The company focuses on improving workflow and communication between sites, sponsors and clinical research organizations.
About SAFE BioPharma
For more information on the SAFE-BioPharma standard for digital identity and digital signatures used in life science and healthcare settings, visit http://www.safe-biopharma.org.
About Trifecta
For more information on the Trifecta Clinical services and technology, visit www.trifectaclinical.com. Trifecta is also a member of the Board of Directors for the Asia Training Consortium. More information can be found at http://www.trainingconsortium.asia.
SAFE-BioPharma® is a trademark of SAFE-BioPharma Association. Any use of this trademark requires approval from SAFE-BioPharma Association.
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20130919006358/en/
